In Vivo Efficacy

Our innovative gene-editing technology increases gene-editing efficiency by 10 to 20 fold, making
our custom model development process faster and more affordable for your research.

In Vivo Efficacy Testing Services

Biocytogen provides high-quality in vivo pharmacology services focused on efficacy evaluation of novel therapeutics. Our in vivo services utilize genetically modified mouse models expressing human targets knocked into the loci of their respective mouse counterparts, severely immunodeficient (B-NDG) mice and their variants, as well as wild type mouse models to support drug discovery and development in the areas of oncology, immuno-oncology, autoimmune diseases, and other immune-mediated inflammatory diseases. We have the capability to test a wide range of biologics including mono- and bispecific antibodies, vaccines, blood components, allergenics,  gene therapy, cells/tissues, and recombinant therapeutic proteins. Some brief examples are provided directly below; for more in-depth information about these in vivo services, please visit these pages.

In vivo antibody efficacy testing

CAR-T efficacy evaluation

CDX & human immune system engrafted models

Frequently Asked Questions

Check-point Antibody Efficacy Study in Immune-competent Syngeneic Mouse Models

Check-point-Antibody-Efficacy

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1 mice, where the extracellular domain of human PD-1 replaces that of mouse PD-1 via genomic knock-in. Mice were grouped when the tumor size reached 150 ± 50 mm3 (n=10). The human PD-1 antibody pembrolizumab significantly inhibited tumor growth, confirming that the B-hPD-1 mouse model is a powerful tool for in vivo anti-human PD-1 efficacy studies. Tumor volume: mean ± SEM (A).  Body weight: mean ± SEM (B).

Bispecific Antibody Efficacy Study

Bispecific-Antibody-Efficacy-Study

Murine colon cancer cells MC38 engineered to express human CD19, MC38-hCD19, were subcutaneously implanted into B-hCD3e mice, where the extracellular domain of human CD3e replaces that of mouse CD3e via genomic knock-in. Mice were grouped (n=6) when the tumor sizes were approximately 150 ± 50 mm3. Blinatumomab, a bispecific antibody targeting human CD3e and human CD19, significantly inhibited tumor growth, demonstrating that the B-hCD3e mice are a powerful model for in vivo efficacy evaluation of anti-hCD3e-based bispecific antibodies. Tumor volume: mean ± SEM (A). Body weight: mean ± SEM (B).

Small Molecule Efficacy Study

Small molecules are an important anti-cancer therapeutic modality, either as single agents or in combination with antibody therapeutics. Biocytogen has rich experience in testing small molecule therapeutics, as illustrated in the following example.

Small-Molecule-Efficacy-Study

Murine colon cancer MC38-hPD-L1 cells were subcutaneously implanted into homozygous B-hPD-1 mice. Mice were grouped when the tumor size reached approximately 150 ± 50 mm3 (n=8). Combination of anti-hPD-1 antibody pembrolizumab and the chemotherapy drug cisplatin showed additional inhibitory effects on tumor growth than individual agents alone in B-hPD-1 mice. Tumor volume: mean ± SEM (A). Body weight: mean ± SEM (B).

CAR-T Cell Efficacy Study in Highly Immune-deficient B-NDG Mice

CAR-T-Cell-Efficacy

Efficacy of various CAR-T therapy targeting human CD20 was evaluated in highly immune-deficient B-NDG mice inoculated with modified human B cell lymphoma cells, B-Raji-Luc-GFP.  Various CAR-T cells were injected i.v. at the same time of B-Raji-Luc-GFP cells. (A) Luciferase signals as an indicator of tumor load in mice treated with different CAR-T cells. (B) Body weight of treated mice. All values are expressed as mean ± SEM.

Back to top